Danaher (DHR) early this morning announced plans to acquire Swiss-based Nobel Biocare for $2.2 billion (CHF 2bn / EUR 1.7bn). Nobel is a leader in the dental implant industry and will become a "cornerstone" of Danaher's dental platform.
Danaher (DHR) early this morning announced plans to acquire Swiss-based Nobel Biocare for $2.2 billion (CHF 2bn / EUR 1.7bn). Nobel is a leader in the dental implant industry and will become a "cornerstone" of Danaher's dental platform.
For the past six months, and probably longer than that, investors and the financial media have been asking themselves or have been asked whether the market is overvalued. The market has marched higher and higher and the S&P 500 is now up 29% for the year. There also seems to be signs of a return of ridiculously-priced IPOs, mostly dot coms and bio-tech stocks in my opinion. People have explained why the market is overvalued by citing Schiller's CAPE ratio or that abnormally high profit margins will eventually revert to the mean.
©Andvari Associates 2021
All Rights Reserved